Andreas Stahl, Hidehiko Nakanishi, Domenico Lepore, Wei-Chi Wu, Noriyuki Azuma, Carlos Jacas, Aditya Athanikar, Robert Vitti, Karen Chu, Pablo Iveli, Fei Zhao, Sarah Schlief, Sergio Leal, Thomas Schmelter, Thomas Miller, Evra Köfüncü, Alistair Fielder
{"title":"通俗易懂的评论:FIREFLEYE的下一项研究为期2年,旨在观察将阿非利西普注射到早产儿视网膜病变患儿的眼睛中效果如何,以及与激光治疗相比其安全性如何。","authors":"Andreas Stahl, Hidehiko Nakanishi, Domenico Lepore, Wei-Chi Wu, Noriyuki Azuma, Carlos Jacas, Aditya Athanikar, Robert Vitti, Karen Chu, Pablo Iveli, Fei Zhao, Sarah Schlief, Sergio Leal, Thomas Schmelter, Thomas Miller, Evra Köfüncü, Alistair Fielder","doi":"10.1177/25158414251321730","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414251321730"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059413/pdf/","citationCount":"0","resultStr":"{\"title\":\"Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment.\",\"authors\":\"Andreas Stahl, Hidehiko Nakanishi, Domenico Lepore, Wei-Chi Wu, Noriyuki Azuma, Carlos Jacas, Aditya Athanikar, Robert Vitti, Karen Chu, Pablo Iveli, Fei Zhao, Sarah Schlief, Sergio Leal, Thomas Schmelter, Thomas Miller, Evra Köfüncü, Alistair Fielder\",\"doi\":\"10.1177/25158414251321730\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23054,\"journal\":{\"name\":\"Therapeutic Advances in Ophthalmology\",\"volume\":\"17 \",\"pages\":\"25158414251321730\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059413/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25158414251321730\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414251321730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment.